YUPELRI® (revefenacin)

About Theravance Biopharma

Theravance Biopharma is dedicated to transforming the treatment of specialty respiratory diseases through the discovery and development of 'Medicines that Make a Difference®'. The company achieved a significant milestone with the FDA approval and commercialization of YUPELRI® for COPD, which is co-commercialized with Viatris in the United States. With a strategic focus on insight, innovation, and managing uncertainty, Theravance Biopharma aims to create shareholder value by advancing its pipeline of organ-selective medicines for serious lung diseases. Its leadership team brings decades of experience from major pharmaceutical companies, guiding the company's integrated research, development, and commercial efforts.

About Cleo Life Sciences

Founded in 2004, Cleo Life Sciences offers a unique hybrid model combining strategic CMC consulting with hands-on, small-scale laboratory prototyping to de-risk and accelerate pharmaceutical development. The company leverages its founder's deep industry experience, having contributed to the CMC development of five commercial drugs and over 60 clinical-stage candidates. Its mission is to transform pharmaceutical development by enabling earlier, faster, and more efficient product and process development for its biopharma clients.

Therapeutic Areas